ReNetX Bio has been awarded a $3 million SBIR Phase II grant from the National Institutes of Health’s National Institute of Neurological Disorders and Stroke.
ReNetX will use the award to advance their lead drug candidate, fusion protein AXER-204, a therapy forfor chronic spinal cord injury.
“This is really important capital that comes at a critical time and will allow us to advance our therapy for people who currently have such limited treatment options,” said ReNetX CEO Erika Smith.